March 25, 2017 4:06 PM ET

Health Care Technology

Company Overview of SafeCode Drug Technologies Corp

Company Overview

SafeCode Drug Technologies Corp., a development stage company, focuses on patenting and developing a commercial application of a voice enabled protector for administering medicine. It intends to develop an application that matches drug name voice templates as a mechanism for unlocking a medication container, such as a syringe or pill box. The company was founded in 2010 and is based in Jerusalem, Israel.

6 Meever HaMiltah Street

Jerusalem,  97761

Israel

Founded in 2010

Phone:

972 5 0783 9976

Fax:

972 5 0783 9976

Key Executives for SafeCode Drug Technologies Corp

Interim Chief Executive Officer and Director
Principal Financial Officer, Principal Accounting Officer, Secretary and Director
Age: 35
Compensation as of Fiscal Year 2016.

SafeCode Drug Technologies Corp Key Developments

SafeCode Drug Technologies Deleted From Other OTC

SafeCode Drug Technologies’s common stock deleted from Other OTC, effective November 29, 2016. The deletion was due to revocation of registration under section 12(j) by SEC.

SEC Orders Hearings On Registration Suspension Or Revocation Against Safecode Drug Technologies For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Safecode Drug Technologies Corp. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Academia Medica Middle East/Africa
ADHD Solutions, Ltd. Middle East/Africa
Aidoc LTD Middle East/Africa
Augmedics LTD Middle East/Africa
BioGaming Lts. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SafeCode Drug Technologies Corp, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.